Company holds 3,500,000 common shares of Surface (about 20%), accounted for under the equity method; carrying value reduced to zero.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Mark L. Baum
Also a director
Chief Executive Officer and Chairman of the Board of Directors
|
53 | Not stated | Not stated | $23,606,274 | |
|
Andrew R. Boll
President, Chief Financial Officer and Corporate Secretary
|
43 | Not stated | Not stated | $10,947,441 | |
|
Francis W. Mullery
President and Chief Executive Officer, ImprimisRx Division
|
50 |
Since 2025
1 year
|
2025 | $1,237,692 | |
|
Amir H. Shojaei
Chief Scientific Officer
|
58 |
Since 2025
1 year
|
2025 | $1,342,627 | |
|
Patrick W. Sullivan
Chief Commercial Officer
|
50 |
Since 2026
this year
|
2025 | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Company holds 3,500,000 common shares of Surface (about 20%), accounted for under the equity method; carrying value reduced to zero.
Harrow's acquisition of remaining equity interests in Melt; Mr. Baum held Melt equity and received cash at closing.
Harrow's acquisition of remaining equity interests in Melt; Mr. Boll held Melt equity and received cash at closing.
Harrow's acquisition of remaining equity interests in Melt; Mr. Saharek held Melt equity, received cash at closing and is entitled to contingent consideration.
Loading...